Literature DB >> 8777281

Effects of glimepiride on insulin and glucagon release from isolated rat pancreas at different glucose concentrations.

F Gregorio1, F Ambrosi, S Cristallini, P Filipponi, F Santeusanio.   

Abstract

The effects of glimepiride, the newest sulphonylureic compound, on pancreatic insulin and glucagon secretion were studied using the classical, isolated, perfused rat pancrease model. The influence of four different environmental glucose conditions (during a glycaemic stimulus with glucose increasing from 5 to 8.33 mM and at stable 0, 5 and 2.22 mM glucose levels) on the effects of glimepiride was also assessed. At a pharmacological concentration glimepiride strongly stimulated beta-cell activity, producing a characteristic biphasic insulin release with a sharp first-phase secretory peak, followed by a prolonged and sustained second phase. Environmental glucose concentrations markedly influenced the extent, but not the pattern of glimepiride-induced insulin secretion, as hormone release dropped significantly when the glucose level was reduced. Glimepiride failed to influence alpha-cell activity at any of the environmental glycaemic levels.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8777281     DOI: 10.1007/bf00571936

Source DB:  PubMed          Journal:  Acta Diabetol        ISSN: 0940-5429            Impact factor:   4.280


  32 in total

Review 1.  Oral hypoglycemic agents.

Authors:  J E Gerich
Journal:  N Engl J Med       Date:  1989-11-02       Impact factor: 91.245

Review 2.  Beta-cell dysfunction induced by chronic hyperglycemia. Current ideas on mechanism of impaired glucose-induced insulin secretion.

Authors:  J L Leahy; S Bonner-Weir; G C Weir
Journal:  Diabetes Care       Date:  1992-03       Impact factor: 19.112

Review 3.  Sulfonylureas in NIDDM.

Authors:  L C Groop
Journal:  Diabetes Care       Date:  1992-06       Impact factor: 19.112

4.  Selective impairment of pancreatic A cell suppression by glucose during acute alloxan-induced insulinopenia: in vitro study on isolated perfused rat pancreas.

Authors:  P Filipponi; F Gregorio; S Cristallini; C Ferrandina; I Nicoletti; F Santeusanio
Journal:  Endocrinology       Date:  1986-07       Impact factor: 4.736

5.  Effects of glimepiride and glibenclamide on insulin and glucagon secretion by the perfused rat pancreas.

Authors:  V Ledercq-Meyer; A G Akkan; J Marchand; W J Malaisse
Journal:  Biochem Pharmacol       Date:  1991-09-27       Impact factor: 5.858

Review 6.  Extrapancreatic effects of sulfonylureas--a comparison between glimepiride and conventional sulfonylureas.

Authors:  G Müller; Y Satoh; K Geisen
Journal:  Diabetes Res Clin Pract       Date:  1995-08       Impact factor: 5.602

7.  Therapeutical concentrations of tolbutamide, glibenclamide, gliclazide and gliquidone at different glucose levels: in vitro effects on pancreatic A- and B-cell function.

Authors:  F Gregorio; F Ambrosi; S Cristallini; M Pedetti; P Filipponi; F Santeusanio
Journal:  Diabetes Res Clin Pract       Date:  1992-12       Impact factor: 5.602

8.  Mechanisms of glucagon secretion during insulin-induced hypoglycemia in man. Role of the beta cell and arterial hyperinsulinemia.

Authors:  G Bolli; P De Feo; G Perriello; S De Cosmo; P Compagnucci; F Santeusanio; P Brunetti; R H Unger
Journal:  J Clin Invest       Date:  1984-04       Impact factor: 14.808

9.  Glucose modulates the amount, but not the kinetics, of insulin released by sulfonylureas.

Authors:  F Gregorio; F Ambrosi; P Filipponi; S Cristallini; F Santeusanio
Journal:  J Diabetes Complications       Date:  1994 Oct-Dec       Impact factor: 2.852

10.  The effect of chronic oral antidiabetic therapy on insulin and glucagon responses to a meal.

Authors:  E Tsalikian; T W Dunphy; N V Bohannon; M Lorenzi; J E Gerich; P H Forsham; J P Kane; J H Karam
Journal:  Diabetes       Date:  1977-04       Impact factor: 9.461

View more
  3 in total

Review 1.  Glimepiride. A review of its use in the management of type 2 diabetes mellitus.

Authors:  H D Langtry; J A Balfour
Journal:  Drugs       Date:  1998-04       Impact factor: 9.546

2.  Egr-1 decreases adipocyte insulin sensitivity by tilting PI3K/Akt and MAPK signal balance in mice.

Authors:  Xiao Yu; Ning Shen; Ming-Liang Zhang; Fei-Yan Pan; Chen Wang; Wei-Ping Jia; Chang Liu; Qian Gao; Xiang Gao; Bin Xue; Chao-Jun Li
Journal:  EMBO J       Date:  2011-08-09       Impact factor: 11.598

Review 3.  The role of sulphonylureas in the management of type 2 diabetes mellitus.

Authors:  Marc Rendell
Journal:  Drugs       Date:  2004       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.